These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38516474)

  • 1. Fluoroquinolones: Neurological Complications and Side Effects in Clinical Practice.
    Anwar AI; Lu L; Plaisance CJ; Daniel CP; Flanagan CJ; Wenger DM; McGregor D; Varrassi G; Kaye AM; Ahmadzadeh S; Cornett EM; Shekoohi S; Kaye AD
    Cureus; 2024 Feb; 16(2):e54565. PubMed ID: 38516474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety considerations of fluoroquinolones in the elderly: an update.
    Stahlmann R; Lode H
    Drugs Aging; 2010 Mar; 27(3):193-209. PubMed ID: 20210367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
    Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
    Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial safety: focus on fluoroquinolones.
    Owens RC; Ambrose PG
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S144-57. PubMed ID: 15942881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with
    Morgan H; Lipka-Lloyd M; Warren AJ; Hughes N; Holmes J; Burton NP; Mahenthiralingam E; Bax BD
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolones: Blessings Or Curses.
    Majalekar PP; Shirote PJ
    Curr Drug Targets; 2020; 21(13):1354-1370. PubMed ID: 32564750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA gyrase, topoisomerase IV, and the 4-quinolones.
    Drlica K; Zhao X
    Microbiol Mol Biol Rev; 1997 Sep; 61(3):377-92. PubMed ID: 9293187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
    Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
    ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of quinolone action and resistance.
    Aldred KJ; Kerns RJ; Osheroff N
    Biochemistry; 2014 Mar; 53(10):1565-74. PubMed ID: 24576155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
    Aldred KJ; McPherson SA; Wang P; Kerns RJ; Graves DE; Turnbough CL; Osheroff N
    Biochemistry; 2012 Jan; 51(1):370-81. PubMed ID: 22126453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mode of action of fluoroquinolones.
    Hooper DC
    Drugs; 1999; 58 Suppl 2():6-10. PubMed ID: 10553698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of quinolones.
    Stahlmann R; Lode H
    Drugs; 1999; 58 Suppl 2():37-42. PubMed ID: 10553703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of binding of fluoroquinolones to the quinolone resistance-determining region of DNA gyrase: towards an understanding of the molecular basis of quinolone resistance.
    Madurga S; Sánchez-Céspedes J; Belda I; Vila J; Giralt E
    Chembiochem; 2008 Sep; 9(13):2081-6. PubMed ID: 18677735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
    Ince D; Zhang X; Silver LC; Hooper DC
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3370-80. PubMed ID: 12384338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
    Kocsis B; Domokos J; Szabo D
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
    Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Moynihan M; Sutcliffe JA; Osheroff N
    J Biol Chem; 1991 Aug; 266(22):14585-92. PubMed ID: 1650363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
    Pan XS; Hamlyn PJ; Talens-Visconti R; Alovero FL; Manzo RH; Fisher LM
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2498-506. PubMed ID: 12121924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.